Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
9,848,515
-
Share change
-
+682,239
-
Total reported value
-
$17,531,878
-
Put/Call ratio
-
44%
-
Price per share
-
$1.78
-
Number of holders
-
65
-
Value change
-
+$1,241,481
-
Number of buys
-
32
-
Number of sells
-
23
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q4 2023
As of 31 Dec 2023,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,848,515 shares.
The largest 10 holders included
BlackRock Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, GSA CAPITAL PARTNERS LLP, NORTHERN TRUST CORP, VANGUARD GROUP INC, Nuveen Asset Management, LLC, MORGAN STANLEY, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
66
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.